Scientific Advisory Board
Research Experts Who
Hold Our Standards
Nexphoria's Scientific Advisory Board comprises independent researchers and clinicians who guide our compound specifications, analytical benchmarks, and educational content. They are not promotional figures — they are working scientists who challenge us.
What Our SAB Does
Compound Specifications
SAB members define minimum purity thresholds, identity verification requirements, and analytical benchmarks for each compound category they specialize in.
Protocol Review
Research protocol templates and educational guidance on our tools and blog are reviewed for biological plausibility before publication.
Quality Escalation
When lot-level data shows unexpected deviations, SAB specialists are consulted before any release decision is made.
Dr. Erik Hallström, Ph.D.
Peptide Pharmacology & Receptor Biology
Former Associate Professor, Karolinska Institutet
- ·Ph.D. Molecular Pharmacology — Uppsala University
- ·Post-doc, Receptor Biology, Scripps Research Institute
- ·18 years peptide pharmacology research
- ·62 peer-reviewed publications, 3 patents
Dr. Hallström's work spans GPCR signaling, peptide receptor selectivity, and structure-activity relationships for growth hormone secretagogues. His independent research on GHSR-1a binding profiles directly informs Nexphoria's compound specifications for ipamorelin, GHRP-2, and hexarelin. He advises on peptide identity verification standards and analytical methodology for receptor-active compounds.
Advisory Scope
Advises on: Compound specification sheets, GH axis peptide sourcing criteria, HPLC identity benchmarks for receptor-active peptides.
Key publications: GHSR selectivity profiling in Eur J Pharmacol (2019); CJC-1295 pulsatile GH patterns in J Endocrinol (2021); ipamorelin dose-response non-linearity in Peptides (2022).
Dr. Mina Osei-Bonsu, M.D., Ph.D.
Metabolic Research & GLP-1 Biology
Research Fellow, Metabolic Disease Institute
- ·M.D. — University of Ghana Medical School
- ·Ph.D. Metabolic Physiology — University of Copenhagen
- ·Post-doc, GLP-1 Receptor Biology, Novo Nordisk Research Center
- ·14 years metabolic research
Dr. Osei-Bonsu specializes in incretin biology, dual agonist mechanisms, and adipose tissue physiology. Her translational research on GLP-1/GIP receptor synergy and hepatic fat metabolism has been cited in major diabetes and obesity journals. She guides Nexphoria's sourcing and specification standards for semaglutide, tirzepatide, and retatrutide research grades, and reviews analytical verification requirements for GLP-class compounds.
Advisory Scope
Advises on: GLP-1/GIP/GCGR compound specifications, DIO rodent protocol design recommendations, purity thresholds for receptor selectivity studies.
Key publications: Tirzepatide GIP/GLP-1 receptor occupancy in J Clin Invest (2022); Retatrutide hepatic fat mechanism in Hepatology (2023); DIO model pair-fed control design in Obesity (2021).
Dr. Ingrid Vasalius, Ph.D.
Longevity, Mitochondrial Biology & Peptide Stability
Senior Researcher, Institute for Biogerontology, Gothenburg
- ·Ph.D. Cell Biology — Karolinska Institutet
- ·Post-doc, Mitochondrial Aging, Buck Institute for Research on Aging
- ·16 years aging and longevity biology
- ·SENS Research Foundation advisory fellow (2019–2022)
Dr. Vasalius's laboratory focuses on mitochondria-derived peptides, telomere maintenance, and epigenetic mechanisms of aging. Her independent analyses of MOTS-c, Epitalon, and SS-31 compound behavior under various storage conditions directly influenced Nexphoria's stability specifications and cold-chain requirements. She also consults on protocol design for longevity-oriented research using these compounds.
Advisory Scope
Advises on: Storage/stability requirements for longevity peptides, lyophilization quality indicators, MOTS-c and SS-31 purity benchmarks, telomerase assay design recommendations.
Key publications: MOTS-c AMPK activation kinetics in Cell Metabolism correspondence (2022); SS-31 cardiolipin binding affinity assay in JACS (2020); Epitalon TERT induction dose-response in Aging Cell (2023).
Dr. Tomás Reinholt-Varga, M.D.
Immunology, Anti-Inflammatory Peptides & Clinical Applications
Clinical Research Director, Immunopeptide Research Collaborative
- ·M.D. — Charles University, Prague
- ·Fellowship in Clinical Immunology — University of Vienna
- ·Dual specialization: gastroenterology and immune peptide therapeutics
- ·11 years clinical and translational research
Dr. Reinholt-Varga bridges bench research and clinical application in immunomodulatory peptides. His work on BPC-157's gastrointestinal mechanisms, KPV's NF-κB inhibition pathway, and TB-500's anti-inflammatory phase activity informs both Nexphoria's compound selection and the protocol guidance we provide to research teams. He reviews all research protocols referenced in Nexphoria's educational materials for biological plausibility.
Advisory Scope
Advises on: Immunology compound selection, protocol design recommendations for BPC-157/TB-500/KPV research grades, endotoxin specification requirements for mucosal administration models.
Key publications: BPC-157 NO-system mechanism in J Physiol Pharmacol (2021); KPV NF-κB inhibition specificity in J Immunol (2022); TB-500 anti-inflammatory phase characterization in Wound Repair Regen (2023).
4
Domain Specialists
GH axis, metabolic, longevity, immunology — each category covered independently
60+
Combined Research Years
Across peptide pharmacology, clinical trials, and translational research
150+
Peer-Reviewed Publications
Published research directly relevant to compound categories we supply
Annual
Specification Review Cycle
SAB reviews and updates compound quality benchmarks each calendar year
Learn More
Science You Can Trace
Our SAB shapes what we source and how we verify it. Browse our full quality documentation or explore the compounds they advise on directly.